At presentation, hormone receptor-negative HER2-negative/low (HR-HER2-) and HER2-positive (HR-HER2 +) breast cancer subtypes occur with greater frequency among IBC patients than among non-IBC patients. Here, ERBB2 is linked to breast cancer.